Altre lingue Alnylam Pharmaceuticals, Inc.

Azioni

ALNY

US02043Q1076

Tempo reale stimato Cboe BZX Altri mercati azionari 20:21:34 30/04/2024			Variaz. 5gg	Var. 1 gen.
145,5 ^USD	-1,26%		-0,16%	-23,81%

13:00	Medison Pharma e Alnylam Pharmaceuticals annunciano l'espansione della loro partnership multiregionale in Europa e Israele, per commercializzare le terapie RNAi in altri mercati Latam e APAC, compresa l'Australia.	CI
08/04	Aggiornamento settoriale: titoli del settore sanitario da piatti a più alti lunedì nel premercato	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia	13:01
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of Their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in Additional Latam and APAC Markets Including Australia	13:00
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results	18/04
Sector Update: Health Care Stocks Flat to Higher Premarket Monday	08/04
Sector Update: Health Care	08/04
RECOMENDACIONES DE LOS ANALISTAS EE.UU./UK : Chevron, Take-Two, Coinbase, Netflix, American Tower...	08/04
Roche and Alnylam present positive results from the Phase II KARDIA-2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled hypertension	08/04
Alnylam Pharmaceuticals Says Phase 2 Trial for Zilebesiran Meets Primary Endpoint	08/04
ANALYST RECOMMENDATIONS : Chevron, Take-Two, Coinbase, Netflix, American Tower...	08/04
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension	07/04
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension	07/04
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session	20/03
Alnylam Launches Hereditary ATTR Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease	14/03
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease	13/03
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY	12/03
ETF der Woche: Auf die Wende der Biotechs setzen	10/03
ETF van de week: inzetten op de ommekeer in de biotech	08/03
ETF de la semaine : miser sur le retournement des Biotechs	08/03
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure	06/03
Alnylam meldet positive KARDIA-2 Topline-Studienergebnisse, die eine klinisch signifikante Blutdrucksenkung bei Zugabe von Zilebesiran zu Standard-Blutdrucksenkern belegen	06/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Alnylam Pharmaceuticals, Inc.

Azioni

ALNY

US02043Q1076

Altre lingue

Filtri